USES OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN

Smart overview of the Invention

The patent application details a novel method of treating various disorders using a co-crystal form of psilocin and psilocybin, referred to as co-crystal Form A. This crystalline form is particularly significant due to its potential applications in addressing neuropsychiatric, neurological, inflammatory disorders, and certain cancers. The co-crystal aims to enhance neuroplasticity, elevate brain-derived neurotrophic factor (BDNF) levels, and reduce neuroinflammation, offering a therapeutic advantage over existing treatments.

Background

Psychedelic compounds found in plants and fungi have long been known for their neuroactive properties, with psilocybin being one of the most prevalent. Psilocybin is metabolized into psilocin in the human body, which is responsible for its psychedelic effects. Despite its instability compared to psilocybin, psilocin's rapid absorption and onset of action make it a compound of interest. The co-crystal formulation combines the benefits of both compounds, potentially offering unique therapeutic properties.

Co-Crystal Form A Characteristics

Co-crystal Form A is characterized by its distinct X-ray powder diffraction (XRPD) pattern, featuring significant peaks at various 2θ angles such as 10.1°, 19.16°, and others. These characteristics are crucial for identifying and confirming the crystalline structure of the co-crystal. The precise formation of this co-crystal is key to its stability and effectiveness in therapeutic applications.

Potential Applications

The co-crystal Form A is proposed for use in treating a wide range of disorders. These include neuropsychiatric conditions like ADHD, autism, depression, anxiety disorders, and PTSD; neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy; inflammatory diseases like multiple sclerosis; and certain cancers including gliomas and meningiomas. The treatment aims to harness the synergistic effects of psilocybin and psilocin to achieve better clinical outcomes.

Conclusion

The development of a co-crystal form combining psilocybin and psilocin presents a promising avenue for treating complex disorders with improved efficacy and reduced side effects. By targeting multiple pathways involved in neuroplasticity and inflammation, this innovative approach could significantly advance therapeutic strategies for challenging conditions that currently have limited treatment options.